![Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnpjschz.2015.39/MediaObjects/41537_2015_Article_BFnpjschz201539_Fig1_HTML.jpg)
Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia
![Aripiprazole (Abilify) in the Treatment of People with Fragile X: An Anecdotal Account • Fragile X Research - FRAXA Research Foundation Aripiprazole (Abilify) in the Treatment of People with Fragile X: An Anecdotal Account • Fragile X Research - FRAXA Research Foundation](https://www.fraxa.org/wp-content/uploads/2020/07/An-Anecdotal-Account-of-Abilify-e1595895473519.jpg)
Aripiprazole (Abilify) in the Treatment of People with Fragile X: An Anecdotal Account • Fragile X Research - FRAXA Research Foundation
![Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996413003411-gr1.jpg)
Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study - ScienceDirect
![PDF] Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents. | Semantic Scholar PDF] Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e3ffcdf6a791460fa6d254247612bd105ed84828/4-Table1-1.png)
PDF] Aripiprazole Lauroxil Long-Acting Injectable: The Latest Addition to Second-Generation Long-Acting Agents. | Semantic Scholar
![Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study - ScienceDirect Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996417301998-gr2.jpg)
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study - ScienceDirect
![Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia - ScienceDirect Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996415003461-gr1.jpg)
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia - ScienceDirect
![Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/20r02799T2.gif)
Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com
![Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnpjschz.2015.39/MediaObjects/41537_2015_Article_BFnpjschz201539_Fig2_HTML.jpg)
Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study | Schizophrenia
![Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com](https://www.psychiatrist.com/wp-content/uploads/2021/06/20r02799T1.gif)
Long-term Efficacy and Tolerability of Adjunctive Aripiprazole for Major Depressive Disorder: Systematic Review and Meta-analysis | Psychiatrist.com
![Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine | CNS Spectrums | Cambridge Core Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine | CNS Spectrums | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20180122065451302-0713:S1092852916000894:S1092852916000894_fig1g.jpeg?pub-status=live)